Bionomics Limited (BNOX)
NASDAQ: BNOX · IEX Real-Time Price · USD
0.911
-0.057 (-5.93%)
At close: May 1, 2024, 3:58 PM
0.920
+0.009 (1.01%)
After-hours: May 1, 2024, 4:00 PM EDT
Bionomics Revenue
Bionomics had revenue of $15.00K in the twelve months ending December 31, 2023. In the fiscal year ending June 30, 2023, Bionomics had annual revenue of $15.21K, a decrease of -91.69%.
Revenue (ttm)
$15.00K
Revenue Growth
-91.69%
P/S Ratio
670.13
Revenue / Employee
$1,875
Employees
8
Market Cap
10.05M USD
Revenue Chart
* The company reports in AUD currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2023 | 15.21K | -167.87K | -91.69% |
Jun 30, 2022 | 183.08K | - | - |
Jun 30, 2021 | 0 | - | - |
Jun 30, 2020 | 32.18K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBNOX News
- 5 weeks ago - Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder - GlobeNewsWire
- 2 months ago - Bionomics to Present at the 2024 BIO CEO & Investor Conference - GlobeNewsWire
- 3 months ago - Bionomics Provides a Review of 2023 and of 2024 Plans - GlobeNewsWire
- 4 months ago - Bionomics to Present at Biotech Showcase™ 2024 - GlobeNewsWire
- 5 months ago - Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting - GlobeNewsWire
- 7 months ago - Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder - GlobeNewsWire
- 7 months ago - Bionomics announces positive results in trial of treatment for PTSD - Market Watch
- 7 months ago - Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD) - GlobeNewsWire